Dualyx
Discovery and development of highly innovative biologicals for the treatment of autoimmune and rare diseases.
Discovery and development of highly innovative biologicals for the treatment of autoimmune and rare diseases.
Dualyx, founded in 2021 and headquartered in Belgium, is a biotechnology startup dedicated to the discovery and development of highly innovative biologicals for the treatment of autoimmune and rare diseases. With a focus on addressing high unmet medical needs, the company aims to create long-lasting treatments for patients. Dualyx secured a significant €40.00M Series A investment on 15 May 2023, with participation from major investors including BioGeneration Ventures, Forbion, Andera Partner, Fountain Healthcare Partners, PMV, V-Bio Ventures, VIB, KU Leuven Research & Development, HTGF | High-Tech Gruenderfonds. This funding is expected to propel the company's research and development efforts, positioning it for future success in the biotechnology and health care industries. Dualyx's slogan "Discovery and development of highly innovative biologicals for the treatment of autoimmune and rare diseases" underscores its commitment to pioneering solutions in the medical field.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | €40.00M | 9 |
|
15 May 2023 |
| Venture Round | Unknown | 1 |
|
01 Jan 2020 |
No recent news or press coverage available for Dualyx.
We care about your data, and we'd love to use cookies make your experience better.